Zalunfiban

Summary

Zalunfiban (CHEMBL3114577) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including st-elevation myocardial infarction and coronary artery disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 386.4 Da · C16H18N8O2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3114577
Name	Zalunfiban
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	71668132
Molecular formula	C16H18N8O2S
Molecular weight	386.4
InChIKey	LTVKZVGAALCRFW-UHFFFAOYSA-N

SMILES: C1CN(CCN1)C2=CC(=O)N3C(=N2)SC(=N3)C4=CC(=CN=C4)NC(=O)CN

IUPAC name: 2-amino-N-[5-(5-oxo-7-piperazin-1-yl-[1,3,4]thiadiazolo[3,2-a]pyrimidin-2-yl)-3-pyridinyl]acetamide

Also known as: RUC-4, RUC4, Zalunfiban, ZALUNFIBAN

Parent form; salt/anhydrous children: CHEMBL4802247

Patent coverage: 56 distinct patent families (85 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	integrin αIIbβ3	Inhibition	7.35

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ST-elevation myocardial infarction	3	MONDO:0041656	EFO:0008585
coronary artery disorder	1	MONDO:0005010	EFO:0001645

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04825743	PHASE3	ACTIVE_NOT_RECRUITING	A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI
NCT04284995	PHASE2	COMPLETED	A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction
NCT03844191	PHASE1	COMPLETED	A Randomized Phase 1 Dose-Escalation Study of Subcutaneously(SC) Administered RUC-4

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).